What is the recommendation for initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTE-ACS?
The recommendation for initial antiplatelet/anticoagulant therapy in patients with definite or likely NSTE-ACS is to give non-enteric coated, chewable aspirin (162 mg to 325 mg) as soon as possible after presentation without contraindications, and to continue a maintenance dose of aspirin (81 mg/d to 325 mg/d) indefinitely. (Level of Evidence: A)